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Regina GONÇALVES, Clair Teixeira do AMARAL, Vanusa Pousada da HORA & Ana Maria Barral de MARTINEZ 
SUMMARY
The herpes simplex virus type 2 (HVS-2) is the most prevalent infection worldwide. It is a cofactor in the acquisition of human 
immunodeficiency virus (HIV) and the persistence of human papillomavirus (HPV). This study evaluated the prevalence of HSV-2, 
using the polymerase chain reaction (PCR), and associated factors in patients treated at the Federal University of Rio Grande (FURG) 
and Basic Health Units (BHU) in Rio Grande, Brazil. The observed prevalence of HSV-2 was 15.6%. Among the 302 women studied, 
158 had received assistance in BHU and 144 were treated at FURG. The prevalence of HSV-2 in these groups was 10.8% and 20.8%, 
respectively, RR 1.9 and p = 0.012. Knowledge about the Pap smear, and the presence of lesions showed no association with HSV-2 
infection. Multivariate analysis showed that the variable that most influenced the risk of HSV-2 infection was the presence of HIV 
infection, with a relative risk of 1.9 and p = 0.04. Discussion: Genital ulcers are an important entry point for HIV, and condom use is 
an important strategy to reduce transmission of HIV and HSV-2.
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INTRODUCTION
Lesions caused by the herpes virus were first documented by 
Hippocrates (460-377 B.C.E.), who called them “herpes,” a word derived 
from reptiles, as a reference to the formation of skin vesicles. The 
herpes simplex virus (HSV) is a DNA virus that belongs to the family 
Herpesviridae. There are two types of HSV: HSV-1, associated with 
non-genital infections, and HSV-2, which causes lesions below the waist, 
especially in the genital area23. However, some studies suggest that the 
prevalence of HSV-1 in genital lesions has not only increased in recent 
years, but may even exceed that of HSV-223.
HSV-2 is one of the most prevalent infections in the world. It is 
estimated that, in the United States, 40-60 million people are infected, with 
an incidence of 1-2 million infections and 600,000-800,000 new cases per 
year29. The latest HSV-2 data published by the Centers for Disease Control 
and Prevention (CDC) at the National Sexually Transmitted Diseases 
Conference in 2010 in Atlanta indicated that the prevalence of HSV-2 is 
still high (16.2%), especially among black women, where rates may be 
as high as 48%. Global prevalence is higher in women compared to men, 
especially among young people8. GARNETT et al. (2004)14 concluded 
that there is a six times greater chance of herpes transmission from men 
to women compared with transmission from women to men. In developed 
countries, where the acquisition of HSV-1 in childhood has been reduced, 
HSV-2 seroprevalence has increased, suggesting a possible protective effect 
of HSV-1 against acquisition of HSV-229. In Brazil, 640,000 new cases of 
genital herpes are diagnosed annually20.
From 1960 to 1970, HSV-2 infection was considered a possible 
causative agent of cervical cancer1,11,12,24,27. The role of HSV-2 in the 
development of cervical cancer has been questioned, since HSV-2 DNA 
was not found in cervical cancer biopsies12. However, women with HSV-2 
have a higher risk of developing cervical carcinoma, and therefore HSV-2 
is considered as a cofactor in certain patients1,7,27. In vitro laboratory data 
and molecular evidence show a possible synergism between HPV and 
HSV-2 in cervical-cancer etiology1. 
In addition, symptomatic or asymptomatic herpetic infections can 
facilitate the acquisition of human immunodeficiency virus (HIV)15. The 
presence of herpes lesions indicates a two-to-three-fold higher risk of HIV 
transmission3,14,16. Therefore, primary prevention of HSV-2 infection may 
be the best available strategy for reducing the risk of infection by HIV9.
Since herpes simplex virus type 2 (HSV-2) is one of the most 
prevalent infections in the world, and is a cofactor in HIV acquisition and 
in the persistence of human papillomavirus (HPV), this study assessed 
HSV-2 prevalence using the polymerase chain reaction (PCR) technique, 
as well as the factors associated with its infection. 
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MATERIALS AND METHODS
This project was approved by the Ethics Committee in Health 
Area Research - CEPAS/FURG, no. 19/2010, CEPAS 67/2010; and by 
the Municipal Center of Health Permanent Education (NEPES), no. 
013/2011.
Sample size was calculated using Epi-info 6.04® software. A 95% 
confidence level was used, with an estimated HSV-2 prevalence between 
12 and 39% (mean 25%)19. A total of 288 women and a sample error 
of 5% were obtained. Samples of cervicovaginal secretions of the 
women included in the study were collected by the gynecologist during 
a gynecological examination, with the use of a VAGISPEC® brush, for 
further molecular analysis and Pap smear. Patients participating in the 
study sought by the average service complaints gynecological, obstetric 
or just to collect the pap smear samples. There was no patient in this 
group with complaints or symptoms of genital ulcer at the time of the 
examination. 
For the molecular analysis, samples were stored in cryogenic tubes 
containing Tris-EDTA (TE) buffer (10 mM Tris-HCl pH 8.5; 1 mM 
EDTA) and sent to the Molecular Biology Laboratory of the School of 
Medicine (FAMED) at the Federal University of Rio Grande (FURG), 
until the extraction of viral DNA. A Pap smear was evaluated as a routine 
procedure at the Pathology Laboratory (FAMED, FURG) and the results 
were later compared to the molecular biology results for HSV-2 and 
HPV viruses.
DNA was extracted from the samples with the commercial kit GFX 
(GE Healthcare) ® GenomicBlood DNA Purification Kit, according to 
the protocol for blood cell extraction.
HSV-2 was detected by two PCR reactions in a nested configuration 
(nested-PCR), adapted to AURELIUS4 and SCHMUTZHARD26 
protocols. First-round amplification of the gene encoding the HSV-
2 viral capsid glycoprotein (gp) was performed using the primers 
HSV21F 5’ TCAGCCCATCCTCCTTCGGCAGTA 3’ and HSV21R 
5’ GATCTGGTACTCGAATGTCTCCG 3’, generating a 184 bp 
fragment; and HSV22F 5’ AGACGTGCGGGTCGTACACG 3’ and 
HSV22R 5’ CGCGCGGTCCCAGATCGGCA 3’ primers, amplifying 
to 100 bp. Consecutive PCR reactions were performed using 6 μL of 
the extracted DNA and 4 μL of the first PCR product, respectively, 1 x 
PCR buffer, 2 mM MgCl2, 0.5 mMdNTP, 1 U of the recombinant enzyme 
Taq DNA polymerase (Invitrogen) and 0.5 μM of HSV21F, HSV21R, 
HSV22F, HSV22R, and H2O Milli-Q QSP primers. Both reactions were 
performed in a final volume of 50 μL. Reaction cycles were performed 
in a thermocycler (Biorad-MyCycler). Reaction conditions for the first 
and second rounds were the same, represented by an initial stage at 94 
ºC for five min for DNA denaturation and 30 subsequent amplification 
cycles at 94 ºC for 30 s for denaturation, 57 ºC for 30 s for annealing, 
72 ºC for one min for primer extension, and a final stage at 72 ºC for 
seven min. Based on electrophoresis, the molecules spin through the 
gel and the results obtained from the molecular techniques are shown. 
Amplicon was observed in 2.5% agarose gel for the second round in a UV 
transilluminator after staining in ethidium bromide (0.5 μg/mL) for 30 
min. The image was photographed using Kodak EDAS software (Kodak 
1D Image Analysis 3.5). Size was compared using the molecular weight 
marker Leidwing Biotec® Ladder 50 bp Puls. A positive and a negative 
cervical sample for HSV-2 were used as reaction controls, in addition 
to a blank reaction omitting any DNA (Fig. 1).
Fo r  H P V  d e t e c t i o n ,  n e s t e d  P C R  w a s  p e r f o r m e d . 
The fi rs t  round was carr ied out  with  external  pr imers: 
M Y 0 9 / M Y 1 1 :  5 ’ C G T C C M A A R G G AWA C T G AT C 3 ’ / 
5’GCMCAGGGWCATAAYAATGG3’18, which amplifies a 450 bp 
fragment of the L1 viral capsid. The second round was held with the 
internal primers: GP5 / 6: 5’TTTGTTACTCTGGTAGATAC3 ‘and 
5’GAAAAATAAACTGTAAATCA3 “28 amplifying a fragment of 150 
bp, also of the L1. Both reactions were performed in a final volume of 
50 μL, containing 2.5 U of Taq DNA polymerase, 25pmol/μL of each 
primer at a concentration of 1.5 mM MgCl, 200 μM of each dNTP and 
Milli-Q H2O QSP. For the first round, 3 μL of extracted DNA was used; 
and for the second round, a 5 μL aliquot of the product was used. The 
reaction conditions for the first round consisted of 40 repeated cycles of 
94 ºC for 30 s for denaturation, 45 ºC for 30 s for annealing, 72 ºC for 
30 s for extension; and for the second round, 40 repeated cycles of 95 ºC 
for one min, 55 ºC for one min and 72 ºC for one min for denaturation, 
annealing and extension, respectively. The amplicon was visualized 
on 1% and 2% agarose gel respectively in the first and second round 
transilluminator (UV), by a system photodocumentation EDAs Kodak 
® after being plated with ethidium bromide solution (10 mg/mL). The 
size was compared with the molecular weight marker Leidwing Biotc ® 
Puls 50 bp ladder. As a positive control reaction, a positive sample was 
used (a fragment of the viral genome of 450 bp) and a negative control 
with omission of any DNA.
Statistical analyses were performed using SPSS software, predicting 
crude analysis, calculation of prevalence ratio, confidence intervals, and 
p value, considering that differences were statistically significant when 
p < 0.05 and using Fisher’s exact test or chi-square. The main variables 
under analysis were: sociodemographic (skin color, age, education, 
income, marital status), gynecological (age at first sexual encounter, 
lifetime number of sexual partners, number of sexual partners in the past 
six months, contraceptive method, previous STD infection, number of 
Fig. 1 - Result of PCR reaction, performed by Thais D. M. Boiler Laboratory of Molecular 
Biology - FAMED / FURG - on 05.10.2011. Negative samples: 1, 2, 3, 5, 6, 7, 8, 10, 12, 14, 
16. Positive samples: 4, 11, 15. Negative Control: 9. Positive Control: 13. Blank (no DNA): 
18. Bookmark Leidwing Biotec®: 17.
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pregnancies, number of deliveries, and knowledge of STDs) and clinical 
and laboratory data, such as Pap smear results. Data on plasma viral 
load and T CD4+ lymphocytes in HIV-positive patients were obtained 
by analysis of medical charts. Multivariate analysis was performed in 
the SPSS software using Poisson regression, followed by a hierarchic 
analysis model in which variables with p = 0.20 were integrated into the 
crude analysis. The first level included demographic and socioeconomic 
variables. The second level included variables that represented risk factors 
for HSV infection. 
RESULTS
Of the 302 patients included in the study, 47 (15.6%) had an HSV-2 
infection. Mean age was 32.7 years, standard deviation (SD) of 13.6, 
and mean family income of R$ 1,400, with 88.1% earning one minimum 
salary or more. Table 1 shows that the only demographic variable 
significantly associated with HSV-2 was education level; patients with 
less than four years of school had a higher prevalence of infection 
compared to patients with more than nine years of school (p = .232).
As to the gynecological history, 71.5% of the patients had their first 
sexual encounter at a mean age of 17 years or less. The mean number of 
total sexual partners was five, and 86.7% reported having one partner over 
the past six months. The obstetric history showed that 62.9% had had two 
or more pregnancies, and 49.7% had two or more deliveries (Table 2).
Table 2 also shows that 18.6% of women reported using contraceptive 
methods. However, contraceptive use showed no statistically significant 
association with prevention of HSV-2 infection. STDs were reported by 
23.3% of the patients, and this group was more likely to have an HSV-2 
infection (p = .053). 
For the Pap smear, 276 (91.4%) patients had normal results, 12 
(4%) had a low to moderate degree of intraepithelial changes, and for 
14 (4.6%) the results of the Pap smear could not be located. Knowledge 
of Pap smear and the presence of lesions in this examination were not 
correlated with a higher risk of HSV-2 infection (Table 2).
Of the 302 patients, 158 had been seen at Basic Health Units 
(BHU) and 144 at UH-FURG outpatient clinics. HSV-2 prevalence 
in these groups was 10.8% and 20.8%, respectively. There was a 
significant difference in HSV prevalence between recruiting locations, 
with confidence interval (95%CI): 1.12-3.36 and p = .012. There was a 
significant difference between HIV-positive and HIV-negative women. 
HIV-positive women were more likely to be infected by HSV-2 (p = .001). 
However, neither viral load nor the CD4 count of HIV-infected women 
was correlated with this infection by HSV-2 (Table 2).
Multivariate analysis showed that the only variable correlated with a 
risk of HSV-2 infection was the presence of HIV, with 95%CI: 1.42-6.33 
and p = .04 (Table 3).
Table 1
Description of the sample and prevalence of herpes virus type 2, and physical and economic risk factors associated with the infection in women in southern Brazil
Variables/Category n (%) HSV+ n (%) Prevalence ratio CI95% p
Age      
≤ 20 years 62 (21.2) 6 (9.4) 1.0  p=0.232b
21-30 years 104 (34.4) 17 (16.3) 1.7 0.73 – 4.19  
31-40 years 57 (18.9) 13 (22.8) 2.4 0.99 – 5.98  
≥ 41 years 77 (25.5) 11 (14.3) 1.5 0.60 – 3.89  
Skin color      
White 202 (66.9) 31 (15.3) 1.0  p=0.503a
Non-white 100 (33.1) 16 (16.0) 1.0 0.60 – 1.81  
Marital status      
With partner 198 (65.6) 27 (13.6) 1.0  p= 0.135a
Without partner 104 (34.4) 20 (19.2) 1.4 0.83 – 2.39  
Education      
9 years or more 55 (19.4) 6 (10.9) 1.0  p=0.032b
5-8 years 68 (24) 5 (7.4) 0.7 0.22 – 2.09  
4 years or less 160 (56.5) 32 (20) 1.8 0.81 – 4.15  
Incomec      
2 or more minimum salaries 109 (41.9) 18 (16.5) 1.0  p=0.871b
1-1.9 minimum salaries 120 (46.2) 20 (16.7) 1.0 0.56 – 1.81  
Under 1 minimum salary 31 (11.9) 4 (12.9) 0.8 0.29 – 2.14  
Smoker      
No 234 (77.5) 34 (14.5) 1.0 0.84 – 2.35 p=0.230a
Yes 68 (22.5) 13 (19.1) 1.3   
aFisher's exact test; bChi-square test; cMinimum salary at the time of the study: R$ 539.00.
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Table 2
Description of the sample and prevalence of herpes virus type 2, and clinical and gynecological risk factors associated with the infection  
in women in southern Brazil
Variables/Category n(%) HSV+ n (%) Prevalence ratio CI95% pa
Age at first sexual encounter      
≥ 18 years 86 (28.5) 14 (16.3) 1.0  p=0.477 a
≤ 17 years 216 (71.5) 33 (15.3) 0.9 0.53 – 1.66  
Lifetime number of partners      
1 partner 85 (28.2) 11 (12.9) 1.0  p=0.595b
2-4 partners 129 (42.9) 19 (14.7) 1.1 0.57 – 2.27  
5 partners or more 87 (28.9) 16 (18.4) 1.4 0.70 – 2.88  
No. of partners over the past 6 months      
None 20 (6.6) 3 (15) 1.0  p=0.489b
1 partner 261(86.7) 39 (14.9) 1.0 0.34 – 2.94  
2 partners or more 20 (6.6) 5 (25) 1.7 0.46 – 6.06  
Number of pregnancies      
Nulligravida 38 (12.6) 8 (21.1) 1.0  p=0.348b
Primigravida 74 (24.5) 9 (12.12) 0.6 0.24 – 1.38  
Secundigravida 71 (23.5) 8 (11.3) 0.5 0.22 – 1.31  
Multigravida 119 (39.4) 22 (18.5) 0.9 0.43 – 1.81  
Number of deliveries      
Nulliparous 81 (26.8) 12 (14.8) 1.0  p=0.934b
Primiparous 71 (23.5) 12 (16.9) 1.1 0.55 – 2.38  
Multiparous 150 (49.7) 22 (15.3) 1.0 0.54 – 1.97  
Uses condom      
Yes 92 (30.5) 17 (18.5) 1.0  p=0.224a
No 210 (69.5) 30 (14.3) 0.8 0.45 – 1.33  
Contraceptive method      
Condom 59 (19.5) 11 (18.6) 1.0  p=0.818b
Hormonal contraceptive 153 (50.7) 23 (15) 0.8 0.41 – 1.55  
None 48 (15.9) 8 (16.7) 0.9 0.39 – 2.04  
Other methods 42 (13.9) 5 (11.9) 0.6 0.24 – 1.70  
Had STD before      
No 242 (80.1) 33 (13.6) 1.0  p=0.053a
Yes 60 (19.9) 14 (23.3) 1.7 0.98 - 2.99  
Knows about herpes      
Yes 167 (55.3) 30 (18.0) 1.0  p=0.131a
No 135 (44.7) 17 (12.6) 0.7 0.40 – 1.22
Knows about STD (HSV, Chlamydia, HPV)      
Yes 200 (66.2) 33 (16.5) 1.0  p=0.326a
No 102 (33.8) 14 (13.7) 0.8 0.47 - 1.48  
Previous knowledge about Pap smear      
Yes 278 (92.1) 45 (16.2) 1.0  p=0.244a
No 24 (7.9) 2 (8.3) 0.5 0.13 – 1.99  
Had Pap smear before      
Yes 241 (79.8) 38 (15.8) 1.0  p=0.512a
No 61 (20.2) 9 (14.8) 0.9 0.48 – 1.83  
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Table 3







Age    
≤ 20 years 1.0  p=0.188
21-30 years 1.1 0.20 - 1.70  
31-40 years 1 0.43 - 2.35  
≥ 41 years 1.5 0.65 - 3.42  
Unit    
UBS 1.0  p=0.145
HU 1.76 0.82 - 3.76  
Has HIV    
No 1.0  p=0.041
Yes 3.0 1.42 - 6.33
Variables/Category n(%) HSV+ n (%) Prevalence ratio CI95% pa
Pap smear      
Normal 276 (91.4) 41 (15.1) 1.0  p=0.279a
Altered 12 (4) 3 (25) 1.7 0.60 – 4.60  
Sample unit origin      
UBS 158 (52.3) 17 (10.8) 1.0 p=0.012a
HU 144 (47.7) 30 (20.8) 1.9 1.12 – 3.36
Patient category      
Pregnant 96 (31.8) 10 (10.4) 1.0  p=0.011b
HIV pregnant 24 (7.9) 8 (33.3) 6.4 3.34 – 12.28  
Gynecological 162 (53.6) 23 (14.2) 1.4 0.68 – 2.74  
HIV gynecological 20 (6.6) 6 (30) 2.9 1.18 – 7.01  
Has HIV      
No 258 (85.4) 33 (12.8) 1.0  p=0.001b
Yes 44 (14.6) 14 (31.8) 2.5 1.45 – 4.26  
CD4      
Equal or lower than 249 15 (37.5) 5 (33.3) 1.0 0.42 – 2.60 p=0.599a
Higher than 350 25 (62.5) 8 (32.0) 1.0   
Viral load      
Undetectable VL 17 (42.5) 7 (41.2) 1.0  p=0.252a
With VL 23 (57.5) 6 (26.1) 0.6 0.26 – 1.55  
Has DNA HPV      
No 247 (81.8) 39 (15.8) 1.0  p=0.502a
Yes 55 (18.2) 8 (14.5) 0.9 0.46 – 1.86  
aFisher's exact test; bChi-square test.
Table 2
Description of the sample and prevalence of herpes virus type 2, and clinical and gynecological risk factors associated with the infection  
in women in southern Brazil (cont.)
DISCUSSION
The prevalence of HSV-2 found in this study using the PCR technique 
was 15.6%. A literature review on data for the prevalence of HSV-2 using 
PCR in Brazil found no earlier publications. However, similar data can 
be found in the international literature, showing that the incidence of 
HSV-2 is still high. A study of women from Gambia, West Africa, found 
an HSV-2 infection rate of 15%2. Similar data were reported by the CDC 
at the National STD Conference in 2010, showing an HSV-2 prevalence 
of 16.2%, a rate that can reach up to 48% in black women. In a study of 
pregnant women conducted at Washington University, HSV-2 DNA was 
detected in 207 of the 716 women included, with a 28.9% rate and 25.7 
to 32.3% standard deviation13. However, in a study performed in six cities 
in the USA on endocervical secretion, HSV-2 DNA was found in 7% of 
the samples3. Although this finding is lower than others reported in the 
literature, this study might have used a different population sampling or 
DNA extraction technique. 
Among demographic variables, only education, with four or fewer 
years of school was associated with HSV-2 acquisition (p = .032), 
suggesting that patients with less education have little knowledge of 
the means of transmission and identification of lesions. Other studies 
showed that black and Hispanic women, lower education level, and low 
per capita family income are risk factors for HSV-2 infection9. Patient 
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skin-color difference was not significant in our study.
Many risk factors have been described in HSV-2 acquisition. Among 
them are early sexual relations, previous history of STDs, and multiple 
sexual partners,8,9,20,29. In the present study, patients who reported 
having had any STDs were more likely to have HSV-2 infection (p = 
.053). In terms of STDs, there was a 31.8% HSV-2 DNA prevalence 
in HIV-positive women, whereas the rate found in the group of HIV-
negative women was 12.8% (p = .001). A study using the molecular 
biology technique to detect HSV-2 in HIV-positive women showed a 
37% prevalence rate of this infection in this group10. A study using a 
seroepidemiological survey of HSV-2 performed in Brazil on 100 HIV-
positive patients showed a prevalence rate of 73% in this population17. 
In addition to a higher HSV-2 prevalence found in HIV-positive 
women, there was also a high rate of HIV-positive pregnant women 
with herpetic infections (33.3%). According to BROWN et al. (2003)6, 
viral excretion is the strongest risk factor for HSV transmission from 
the mother to the newborn at birth. A study conducted by PATTERSON 
et al. (2011)22 showed that pregnant women co-infected with HSV-2/
HIV are more likely to transmit HSV at birth than are HIV-negative 
pregnant women. This finding draws attention to a little-studied 
situation in Brazil, namely, the risk of vertical transmission of HSV-2 
in asymptomatic HIV-positive pregnant women. Therefore, women 
infected by HSV-2 should be tested for HIV and adopt prevention 
strategies, such as using a condom.
Several studies have associated HSV-2 infection with a higher 
risk of developing cervical carcinoma, and HSV-2 infection has been 
considered a cofactor of this disease1,11,12,24,27. Molecular evidence shows 
a possible synergism between HPV and HSV-2 in the etiology of cervical 
cancer; HSV-2 infection could support the persistence of HPV infection, 
increasing the risk of cervical lesions caused by this virus1. The results 
of this study showed that 95.8% of the patients had a normal Pap smear 
and only 4.2% had a low- to high-degree intraepithelial lesion. HSV-2 
prevalence was 15.1% in women with normal Pap smear and 25% in 
women with altered Pap smear. Although the herpetic infection rate was 
higher in the second group, it was not associated with a significant risk of 
acquiring this infection. In addition, when HSV-2 prevalence was assessed 
in relation to HPV, women with HPV had an HSV-2 rate of 14.5%, 
whereas in the HPV-negative group the rate was 15.8%. Therefore, this 
study found no association between HSV/HPV co-infection nor a higher 
risk of intraepithelial lesions in the HSV-2-positive group.
Another hypothesis investigated in this study was the possibility of 
a higher herpetic infection rate among women seen in a tertiary health 
center (UH-FURG) in relation to women seen in a primary center 
(BHU). HSV-2 prevalence among UH women was 20.8%, whereas it 
was 10.8% at BHUs. Therefore, women seen at the tertiary health center 
showed a higher risk of being HSV-2-positive (p = .012). This finding 
suggests that the population seen at the UH has behavioral, clinical and/
or gynecological characteristics that differ from the population seen at the 
BHUs, showing that the former group requires more attention, follow-up 
and information regarding STDs.
In this study, we observed that HIV-positive patients had a higher 
prevalence of infection with HSV-2. Therefore, the herpes infection 
can be a gateway to HIV, and conversely, HIV can be a risk factor for 
acquisition of herpes14,16,17,22,25. Although no study patient had a genital 
ulcer present at the time of collection, they could have had these injuries 
at some point in their lives. STD presence increases the risk of HIV 
infection, especially when genital ulcers are present8,9,20,29. In addition, 
herpetic infection is more recurrent, more extensive, and has more 
serious symptoms in HIV-positive patients, and may also influence 
the clinical worsening of these patients. Thus, more attention should 
be given to herpetic infection in HIV-positive patients. It is extremely 
important to prevent such infections using awareness campaigns, 
such as education regarding use of a condom and risk behaviors for 
virus acquisition, and more attention from health professionals in 
patients with typical lesions or recurrent genital symptoms. An HSV-
2 diagnosis should be requested, preventing future virus transmission 
and controlling both infections.
RESUMO
Prevalência do herpes vírus tipo 2 e fatores de risco associados a 
sua infecção em mulheres do sul do Brasil
O vírus herpes simplex tipo 2 (HVS-2) é uma das infecções mais 
prevalentes em todo o mundo. Considera-se um co-factor na aquisição 
do vírus da imunodeficiência humana (HIV) e na persistência do 
papilomavirus humano (HPV). Este estudo tem como objetivo avaliar a 
prevalência de HSV-2 usando a reação em cadeia da polimerase (PCR) e 
fatores associados em pacientes atendidos na Universidade Federal do Rio 
Grande e em Unidades Básicas de Saúde (UBS) do Rio Grande, Brasil. 
A prevalência de HSV-2 encontrada neste estudo foi de 15,6%. Entre as 
302 mulheres estudadas, 158 haviam recebido assistência na UBS e 144 
foram atendidos na FURG. A prevalência de HSV-2 nestes grupos foi 
de 10,8 e 20,8%, respectivamente, com RR: 1,9 e p = 0,012. Conhecer 
o exame de Papanicolaou, e presença de lesão não teve associação com 
infecção HSV-2. A análise multivariada mostrou que a variável que 
influencia no risco de infecção HSV-2 foi o paciente ter HIV, com risco 
relativo 1,9 e p = 0,04. Discussão: As úlceras genitais são importante 
porta de entrada para o vírus HIV e o uso do preservativo é estratégia 
importante para reduzir a transmissão do HIV e do HSV-2.
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